See more : Emilia Development (O.F.G) Ltd. (EMDV.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Nevro Corp. (NVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nevro Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Tasty plc (TAST.L) Income Statement Analysis – Financial Results
- Unicharm Corporation (UNICY) Income Statement Analysis – Financial Results
- Atresmedia Corporación de Medios de Comunicación, S.A. (ATVDY) Income Statement Analysis – Financial Results
- Seiren Co.,Ltd. (3569.T) Income Statement Analysis – Financial Results
- Janison Education Group Limited (JAN.AX) Income Statement Analysis – Financial Results
Nevro Corp. (NVRO)
About Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 425.17M | 406.37M | 386.91M | 362.05M | 390.26M | 387.29M | 326.67M | 228.50M | 69.61M | 32.57M | 23.50M | 18.15M |
| Cost of Revenue | 135.11M | 130.00M | 120.86M | 112.15M | 121.91M | 113.97M | 98.98M | 75.43M | 28.12M | 11.28M | 9.47M | 7.53M |
| Gross Profit | 290.06M | 276.37M | 266.04M | 249.90M | 268.35M | 273.32M | 227.69M | 153.07M | 41.49M | 21.30M | 14.03M | 10.62M |
| Gross Profit Ratio | 68.22% | 68.01% | 68.76% | 69.02% | 68.76% | 70.57% | 69.70% | 66.99% | 59.60% | 65.38% | 59.69% | 58.53% |
| Research & Development | 54.42M | 53.07M | 47.67M | 45.60M | 59.02M | 48.46M | 37.56M | 33.73M | 21.38M | 19.82M | 20.35M | 15.66M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 334.70M | 322.14M | 309.31M | 267.15M | 305.81M | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 18.83M | 14.09M |
| Other Expenses | 246.00K | 511.00K | -814.00K | -495.00K | -697.00K | -1.16M | 1.07M | -1.10M | -1.74M | -1.88M | -654.00K | 186.00K |
| Operating Expenses | 389.37M | 375.20M | 356.98M | 312.75M | 364.83M | 315.07M | 257.27M | 176.15M | 103.85M | 49.60M | 39.18M | 29.75M |
| Cost & Expenses | 524.48M | 505.20M | 477.84M | 424.90M | 486.73M | 429.03M | 356.25M | 251.59M | 131.97M | 60.88M | 48.65M | 37.28M |
| Interest Income | 14.17M | 4.02M | 671.00K | 2.96M | 6.02M | 4.87M | 3.16M | 1.69M | 575.00K | 0.00 | 153.00K | 139.00K |
| Interest Expense | 8.01M | 6.43M | 19.75M | 21.81M | 10.93M | 10.40M | 9.90M | 6.39M | 2.73M | 16.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.54M | 10.33M | 8.68M | 8.19M | 7.80M | 3.89M | 2.51M | 1.72M | 614.00K | 96.00K | 47.00K | 39.00K |
| EBITDA | -78.31M | 21.02M | -102.40M | -52.21M | -83.36M | -37.86M | -22.84M | -22.04M | -62.92M | -30.09M | -25.10M | -19.09M |
| EBITDA Ratio | -18.42% | -50.16% | -18.33% | -17.36% | -24.72% | -10.78% | -9.05% | -9.55% | -89.60% | -86.90% | -106.83% | -105.18% |
| Operating Income | -99.31M | -98.84M | -90.93M | -62.85M | -96.48M | -41.74M | -29.58M | -23.08M | -62.37M | -28.31M | -25.15M | -19.13M |
| Operating Income Ratio | -23.36% | -24.32% | -23.50% | -17.36% | -24.72% | -10.78% | -9.05% | -10.10% | -89.60% | -86.90% | -107.03% | -105.40% |
| Total Other Income/Expenses | 1.45M | -1.90M | -19.89M | -19.35M | -5.61M | -6.69M | -5.67M | -7.07M | -3.90M | -1.90M | -501.00K | 325.00K |
| Income Before Tax | -97.86M | 4.26M | -130.83M | -82.20M | -102.09M | -48.44M | -35.25M | -30.16M | -66.27M | -30.20M | -25.65M | -18.81M |
| Income Before Tax Ratio | -23.02% | 1.05% | -33.81% | -22.70% | -26.16% | -12.51% | -10.79% | -13.20% | -95.20% | -92.72% | -109.16% | -103.61% |
| Income Tax Expense | -5.65M | 1.26M | 534.00K | 868.00K | 1.60M | 768.00K | 1.41M | 1.62M | 1.17M | 478.00K | 362.00K | 162.00K |
| Net Income | -92.21M | 3.00M | -131.36M | -83.07M | -103.69M | -49.21M | -36.66M | -31.78M | -67.43M | -30.68M | -26.01M | -18.97M |
| Net Income Ratio | -21.69% | 0.74% | -33.95% | -22.94% | -26.57% | -12.70% | -11.22% | -13.91% | -96.88% | -94.19% | -110.70% | -104.50% |
| EPS | -2.56 | 0.09 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| EPS Diluted | -2.56 | 0.08 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| Weighted Avg Shares Out | 35.98M | 35.32M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
| Weighted Avg Shares Out (Dil) | 35.98M | 35.53M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies REDWOOD CITY, Calif. , Feb. 1, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO),...
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results...
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic...
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic back and leg pain, non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN) REDWOOD CITY, Calif. , Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a...
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Nevro laying off 63 employees; revenue to beat analyst estimates
Nevro Corp.'s stock NVRO, +5.27% rose by 0.3% in premarket trades on Tuesday after the Redwood City, Calif.-based medical device maker said it would reduce its work force by 5% or 63 people.
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
Fourth-Quarter 2023 Worldwide Revenue Exceeds Company's Expectations Announces Restructuring to Support Company's Long-Term Growth and Profitability REDWOOD CITY, Calif. , Jan. 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions...
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in...
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Source: https://incomestatements.info
Category: Stock Reports